Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 33

1.

LY2157299 Monohydrate, a TGF-βR1 Inhibitor, Suppresses Tumor Growth and Ascites Development in Ovarian Cancer.

Zhang Q, Hou X, Evans BJ, VanBlaricom JL, Weroha SJ, Cliby WA.

Cancers (Basel). 2018 Aug 7;10(8). pii: E260. doi: 10.3390/cancers10080260.

2.

Senolytics improve physical function and increase lifespan in old age.

Xu M, Pirtskhalava T, Farr JN, Weigand BM, Palmer AK, Weivoda MM, Inman CL, Ogrodnik MB, Hachfeld CM, Fraser DG, Onken JL, Johnson KO, Verzosa GC, Langhi LGP, Weigl M, Giorgadze N, LeBrasseur NK, Miller JD, Jurk D, Singh RJ, Allison DB, Ejima K, Hubbard GB, Ikeno Y, Cubro H, Garovic VD, Hou X, Weroha SJ, Robbins PD, Niedernhofer LJ, Khosla S, Tchkonia T, Kirkland JL.

Nat Med. 2018 Aug;24(8):1246-1256. doi: 10.1038/s41591-018-0092-9. Epub 2018 Jul 9.

PMID:
29988130
3.

Transcriptomic Characterization of Endometrioid, Clear Cell, and High-Grade Serous Epithelial Ovarian Carcinoma.

Fridley BL, Dai J, Raghavan R, Li Q, Winham SJ, Hou X, Weroha SJ, Wang C, Kalli KR, Cunningham JM, Lawrenson K, Gayther SA, Goode EL.

Cancer Epidemiol Biomarkers Prev. 2018 Jul 2. doi: 10.1158/1055-9965.EPI-17-0728. [Epub ahead of print]

PMID:
29967001
4.

Constitutive Interferon Pathway Activation in Tumors as an Efficacy Determinant Following Oncolytic Virotherapy.

Kurokawa C, Iankov ID, Anderson SK, Aderca I, Leontovich AA, Maurer MJ, Oberg AL, Schroeder MA, Giannini C, Greiner SM, Becker MA, Thompson EA, Haluska P, Jentoft ME, Parney IF, Weroha SJ, Jen J, Sarkaria JN, Galanis E.

J Natl Cancer Inst. 2018 May 16. doi: 10.1093/jnci/djy033. [Epub ahead of print]

PMID:
29788332
5.

Chemotherapy Acute Infusion Reactions: A Qualitative Report of the Perspectives of Patients With Cancer.

Bartlett DJ, Childs DS, Breitkopf CR, Grudem ME, Mitchell JL, Looker SA, Ridgeway JL, Lee JL, Butterfield JH, Weroha SJ, Jatoi A.

Am J Hosp Palliat Care. 2018 Jan 1:1049909118773995. doi: 10.1177/1049909118773995. [Epub ahead of print]

PMID:
29724109
6.

Uterine serous carcinoma: Reassessing effectiveness of platinum-based adjuvant therapy.

Tortorella L, Langstraat CL, Weaver AL, McGree ME, Bakkum-Gamez JN, Dowdy SC, Cliby WA, Keeney GL, Sherman ME, Weroha SJ, Mariani A, Podratz KC.

Gynecol Oncol. 2018 May;149(2):291-296. doi: 10.1016/j.ygyno.2018.02.022. Epub 2018 Mar 14.

PMID:
29550183
7.

Dual inhibition of AKT-mTOR and AR signaling by targeting HDAC3 in PTEN- or SPOP-mutated prostate cancer.

Yan Y, An J, Yang Y, Wu D, Bai Y, Cao W, Ma L, Chen J, Yu Z, He Y, Jin X, Pan Y, Ma T, Wang S, Hou X, Weroha SJ, Karnes RJ, Zhang J, Westendorf JJ, Wang L, Chen Y, Xu W, Zhu R, Wang D, Huang H.

EMBO Mol Med. 2018 Apr;10(4). pii: e8478. doi: 10.15252/emmm.201708478.

8.

Investigation of factors affecting the efficacy of 3C23K, a human monoclonal antibody targeting MISIIR.

Gill SE, Zhang Q, Keeney GL, Cliby WA, Weroha SJ.

Oncotarget. 2017 Jul 27;8(49):85214-85223. doi: 10.18632/oncotarget.19620. eCollection 2017 Oct 17.

9.

PDX-MI: Minimal Information for Patient-Derived Tumor Xenograft Models.

Meehan TF, Conte N, Goldstein T, Inghirami G, Murakami MA, Brabetz S, Gu Z, Wiser JA, Dunn P, Begley DA, Krupke DM, Bertotti A, Bruna A, Brush MH, Byrne AT, Caldas C, Christie AL, Clark DA, Dowst H, Dry JR, Doroshow JH, Duchamp O, Evrard YA, Ferretti S, Frese KK, Goodwin NC, Greenawalt D, Haendel MA, Hermans E, Houghton PJ, Jonkers J, Kemper K, Khor TO, Lewis MT, Lloyd KCK, Mason J, Medico E, Neuhauser SB, Olson JM, Peeper DS, Rueda OM, Seong JK, Trusolino L, Vinolo E, Wechsler-Reya RJ, Weinstock DM, Welm A, Weroha SJ, Amant F, Pfister SM, Kool M, Parkinson H, Butte AJ, Bult CJ.

Cancer Res. 2017 Nov 1;77(21):e62-e66. doi: 10.1158/0008-5472.CAN-17-0582.

PMID:
29092942
10.

Loss of FOXO1 Cooperates with TMPRSS2-ERG Overexpression to Promote Prostate Tumorigenesis and Cell Invasion.

Yang Y, Blee AM, Wang D, An J, Pan Y, Yan Y, Ma T, He Y, Dugdale J, Hou X, Zhang J, Weroha SJ, Zhu WG, Wang YA, DePinho RA, Xu W, Huang H.

Cancer Res. 2017 Dec 1;77(23):6524-6537. doi: 10.1158/0008-5472.CAN-17-0686. Epub 2017 Oct 6.

11.

LMO1 Synergizes with MYCN to Promote Neuroblastoma Initiation and Metastasis.

Zhu S, Zhang X, Weichert-Leahey N, Dong Z, Zhang C, Lopez G, Tao T, He S, Wood AC, Oldridge D, Ung CY, van Ree JH, Khan A, Salazar BM, Lummertz da Rocha E, Zimmerman MW, Guo F, Cao H, Hou X, Weroha SJ, Perez-Atayde AR, Neuberg DS, Meves A, McNiven MA, van Deursen JM, Li H, Maris JM, Look AT.

Cancer Cell. 2017 Sep 11;32(3):310-323.e5. doi: 10.1016/j.ccell.2017.08.002. Epub 2017 Aug 31.

PMID:
28867147
12.

Prevention of Human Lymphoproliferative Tumor Formation in Ovarian Cancer Patient-Derived Xenografts.

Butler KA, Hou X, Becker MA, Zanfagnin V, Enderica-Gonzalez S, Visscher D, Kalli KR, Tienchaianada P, Haluska P, Weroha SJ.

Neoplasia. 2017 Aug;19(8):628-636. doi: 10.1016/j.neo.2017.04.007. Epub 2017 Jun 26.

13.

Phase 2 trial of everolimus and letrozole in relapsed estrogen receptor-positive high-grade ovarian cancers.

Colon-Otero G, Weroha SJ, Foster NR, Haluska P, Hou X, Wahner-Hendrickson AE, Jatoi A, Block MS, Dinh TA, Robertson MW, Copland JA.

Gynecol Oncol. 2017 Jul;146(1):64-68. doi: 10.1016/j.ygyno.2017.04.020. Epub 2017 Apr 28.

PMID:
28461031
14.

Characterization of fusion genes in common and rare epithelial ovarian cancer histologic subtypes.

Earp MA, Raghavan R, Li Q, Dai J, Winham SJ, Cunningham JM, Natanzon Y, Kalli KR, Hou X, Weroha SJ, Haluska P, Lawrenson K, Gayther SA, Wang C, Goode EL, Fridley BL.

Oncotarget. 2017 Jul 18;8(29):46891-46899. doi: 10.18632/oncotarget.16781.

15.

In vivo anti-tumor activity of the PARP inhibitor niraparib in homologous recombination deficient and proficient ovarian carcinoma.

AlHilli MM, Becker MA, Weroha SJ, Flatten KS, Hurley RM, Harrell MI, Oberg AL, Maurer MJ, Hawthorne KM, Hou X, Harrington SC, McKinstry S, Meng XW, Wilcoxen KM, Kalli KR, Swisher EM, Kaufmann SH, Haluska P.

Gynecol Oncol. 2016 Nov;143(2):379-388. doi: 10.1016/j.ygyno.2016.08.328. Epub 2016 Sep 8.

16.

Ridaforolimus (MK-8669) synergizes with Dalotuzumab (MK-0646) in hormone-sensitive breast cancer.

Becker MA, Hou X, Tienchaianada P, Haines BB, Harrington SC, Weroha SJ, Sathyanarayanan S, Haluska P.

BMC Cancer. 2016 Oct 20;16(1):814.

17.

Ureteral obstruction in cancer patients: a qualitative study.

Kumar A, Mynderse L, Patel K, Grudem M, Bakkum-Gamez J, Longenbach S, Block MS, Pitot HC, Garovic V, Weroha SJ, Jatoi A.

Psychooncology. 2016 May;25(5):605-9. doi: 10.1002/pon.3889. Epub 2015 Jun 22. No abstract available.

PMID:
26101949
18.

Conventional chemotherapy and oncogenic pathway targeting in ovarian carcinosarcoma using a patient-derived tumorgraft.

Glaser G, Weroha SJ, Becker MA, Hou X, Enderica-Gonzalez S, Harrington SC, Haluska P.

PLoS One. 2015 May 11;10(5):e0126867. doi: 10.1371/journal.pone.0126867. eCollection 2015.

19.

Tumorgrafts as in vivo surrogates for women with ovarian cancer.

Weroha SJ, Becker MA, Enderica-Gonzalez S, Harrington SC, Oberg AL, Maurer MJ, Perkins SE, AlHilli M, Butler KA, McKinstry S, Fink S, Jenkins RB, Hou X, Kalli KR, Goodman KM, Sarkaria JN, Karlan BY, Kumar A, Kaufmann SH, Hartmann LC, Haluska P.

Clin Cancer Res. 2014 Mar 1;20(5):1288-97. doi: 10.1158/1078-0432.CCR-13-2611. Epub 2014 Jan 7.

20.

Dual HER/VEGF receptor targeting inhibits in vivo ovarian cancer tumor growth.

Becker MA, Farzan T, Harrington SC, Krempski JW, Weroha SJ, Hou X, Kalli KR, Wong TW, Haluska P.

Mol Cancer Ther. 2013 Dec;12(12):2909-16. doi: 10.1158/1535-7163.MCT-13-0547. Epub 2013 Oct 15.

21.

The insulin-like growth factor system in cancer.

Weroha SJ, Haluska P.

Endocrinol Metab Clin North Am. 2012 Jun;41(2):335-50, vi. doi: 10.1016/j.ecl.2012.04.014. Review.

22.

Quantifying insulin receptor isoform expression in FFPE breast tumors.

Harrington SC, Weroha SJ, Reynolds C, Suman VJ, Lingle WL, Haluska P.

Growth Horm IGF Res. 2012 Jun-Aug;22(3-4):108-15. doi: 10.1016/j.ghir.2012.04.001. Epub 2012 Apr 30.

23.

IGFBP ratio confers resistance to IGF targeting and correlates with increased invasion and poor outcome in breast tumors.

Becker MA, Hou X, Harrington SC, Weroha SJ, Gonzalez SE, Jacob KA, Carboni JM, Gottardis MM, Haluska P.

Clin Cancer Res. 2012 Mar 15;18(6):1808-17. doi: 10.1158/1078-0432.CCR-11-1806. Epub 2012 Jan 27.

24.

Oncogenic pathways, molecularly targeted therapies, and highlighted clinical trials in non-small-cell lung cancer (NSCLC).

Reungwetwattana T, Weroha SJ, Molina JR.

Clin Lung Cancer. 2012 Jul;13(4):252-66. doi: 10.1016/j.cllc.2011.09.004. Epub 2011 Dec 8. Review.

PMID:
22154278
25.

Phase II trial of lapatinib and topotecan (LapTop) in patients with platinum-refractory/resistant ovarian and primary peritoneal carcinoma.

Weroha SJ, Oberg AL, Ziegler KL, Dakhilm SR, Rowland KM, Hartmann LC, Moore DF Jr, Keeney GL, Peethambaram PP, Haluska P.

Gynecol Oncol. 2011 Jul;122(1):116-20. doi: 10.1016/j.ygyno.2011.03.030. Epub 2011 Apr 22.

26.

Specific overexpression of cyclin E·CDK2 in early preinvasive and primary breast tumors in female ACI rats induced by estrogen.

Weroha SJ, Lingle WL, Hong Y, Li SA, Li JJ.

Horm Cancer. 2010 Feb;1(1):34-43. doi: 10.1007/s12672-009-0004-z. Epub 2010 Feb 10.

PMID:
21761349
27.

Treatment of hormone-refractory prostate cancer, HRPC, remains challenging.

Weroha SJ, Quevedo JF.

Med Oncol. 2010 Jun;27(2):569. doi: 10.1007/s12032-009-9249-1. Epub 2009 Jun 16. No abstract available.

PMID:
19533421
28.

IGF-1 receptor inhibitors in clinical trials--early lessons.

Weroha SJ, Haluska P.

J Mammary Gland Biol Neoplasia. 2008 Dec;13(4):471-83. doi: 10.1007/s10911-008-9104-6. Epub 2008 Nov 21. Review.

29.

Overexpression of cyclins D1 and D3 during estrogen-induced breast oncogenesis in female ACI rats.

Weroha SJ, Li SA, Tawfik O, Li JJ.

Carcinogenesis. 2006 Mar;27(3):491-8. Epub 2005 Nov 25.

PMID:
16311245
30.

Estrogen mediates Aurora-A overexpression, centrosome amplification, chromosomal instability, and breast cancer in female ACI rats.

Li JJ, Weroha SJ, Lingle WL, Papa D, Salisbury JL, Li SA.

Proc Natl Acad Sci U S A. 2004 Dec 28;101(52):18123-8. Epub 2004 Dec 15.

31.
32.

Ploidy differences between hormone- and chemical carcinogen-induced rat mammary neoplasms: comparison to invasive human ductal breast cancer.

Li JJ, Papa D, Davis MF, Weroha SJ, Aldaz CM, El-Bayoumy K, Ballenger J, Tawfik O, Li SA.

Mol Carcinog. 2002 Jan;33(1):56-65.

PMID:
11807958
33.

ER and PR in renomedullary interstitial cells during Syrian hamster estrogen-induced tumorigenesis: evidence for receptor-mediated oncogenesis.

Li JJ, Weroha SJ, Davis MF, Tawfik O, Hou X, Li SA.

Endocrinology. 2001 Sep;142(9):4006-14.

PMID:
11517180

Supplemental Content

Loading ...
Support Center